Brian M. Wolpin, Wungki Park, Ignacio Garrido-Laguna, A Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S. Azad, J. Randolph Hecht, Sai Hong Ignatius Ou, Tong Lin, Sumit Kar, Lin Tao, Rashmi Vora, Aparna Hegde, Kyaw Aung, David S. Hong
BACKGROUND: mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: -mutated PDAC. RESULTS: G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. CONCLUSIONS: -mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).